Antiviral therapy

Abstract

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

What is claimed is: 
     
         1 . A combination comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and abacavir, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The combination according to  claim 1  wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         3 . The combination according to  claim 1  wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
     
     
         4 . The combination according to  claim 1 , further comprising lamivudine or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The combination according to  claim 4 , wherein the pharmaceutically acceptable salt of the compound of formula (I) is a sodium salt, and wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         6 . A combination comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and abacavir, or a pharmaceutically acceptable salt thereof, and lamivudine. 
     
     
         7 . A method of treatment of HIV infection comprising administering to a human, a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and abacavir, or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The method according to  claim 7  wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         9 . The method according to  claim 7  wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
     
     
         10 . The method according to  claim 7 , further comprising the administration of lamivudine or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The method according to  claim 7 , wherein the pharmaceutically acceptable salt of the compound of formula (I) is a sodium salt, and wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         12 . A method of treatment of HIV infection comprising administering to a human of the compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and abacavir, or a pharmaceutically acceptable salt thereof, and lamivudine. 
     
     
         13 . A pharmaceutical composition comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and abacavir, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor. 
     
     
         14 . The pharmaceutical composition according to  claim 13  wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         15 . The pharmaceutical composition according to  claim 13  wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
     
     
         16 . The pharmaceutical composition according to  claim 13  further comprising lamivudine or a pharmaceutically acceptable salt thereof. 
     
     
         17 . The combination according to  claim 1  wherein the combination is administered simultaneously. 
     
     
         18 . The combination according to  claim 6  wherein the combination is administered simultaneously. 
     
     
         19 . The combination according to  claim 1  wherein the combination is administered sequentially. 
     
     
         20 . The combination according to  claim 6  wherein the combination is administered sequentially. 
     
     
         21 . A method of treatment according to  claim 7  wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, and abacavir or a pharmaceutically acceptable salt thereof, are administered simultaneously. 
     
     
         22 . A method of treatment according to  claim 12  wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof, and lamivudine are administered simultaneously. 
     
     
         23 . A method of treatment according to  claim 7  wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, and abacavir or a pharmaceutically acceptable salt thereof, are administered sequentially. 
     
     
         24 . A method of treatment according to  claim 12  wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof, and lamivudine are administered sequentially. 
     
     
         25 . A patient pack comprising a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, and abacavir or a pharmaceutically acceptable salt thereof.